{"filing":{"accession_number":"0001104659-26-082719","cik":"0001279704","ticker":"CLRB","company_name":"Cellectar Biosciences, Inc.","form":"8-K","filing_date":"2026-07-10","report_date":null,"primary_document":"tm2620219d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1279704/000110465926082719/tm2620219d1_8k.htm"},"events":[{"id":17414,"run_id":15589,"accession_number":"0001104659-26-082719","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Cellectar Biosciences held its Annual Meeting on July 7, 2026, with shareholders voting on six proposals: election of Class III directors (Andrew Gu and Douglas J. Swirsky), approval of a 2,000,000-share increase to the 2021 Stock Incentive Plan, ratification of Deloitte \u0026 Touche LLP as independent auditor, advisory approval of named executive officer compensation, approval of warrant exercise for up to 39,618,078 shares, and adjournment. The detailed vote tallies for each proposal are disclosed.","company_name":"Cellectar Biosciences, Inc.","ticker":"CLRB","filing_date":"2026-07-10","form":"8-K","submitted_at":null,"items":[{"id":15870,"accession_number":"0001104659-26-082719","item_number":"5.02","item_title":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on stockholder approval of an amendment to the 2021 Stock Incentive Plan increasing the share reserve by 2,000,000 shares. This is a compensatory arrangement affecting equity grants available to officers and directors, fitting the exec_compensation category. The materiality is high given the substantial increase in equity capacity and shareholder vote approval on July 7, 2026.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-11T00:15:58.677203+00:00","company_name":"","ticker":null,"filing_date":""},{"id":15871,"accession_number":"0001104659-26-082719","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This Item 5.07 discloses the results of Cellectar Biosciences' Annual Meeting held on July 7, 2026, including voting outcomes on six proposals: election of Class III directors (Andrew Gu and Douglas J. Swirsky), approval of a 2,000,000-share increase to the 2021 Stock Incentive Plan, ratification of Deloitte \u0026 Touche LLP as independent auditor, advisory approval of named executive officer compensation, approval of warrant exercise for up to 39,618,078 shares, and adjournment (rendered moot). The detailed vote tallies for each proposal are material to investors assessing governance and capital structure decisions.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-11T00:15:58.677203+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":15870,"accession_number":"0001104659-26-082719","item_number":"5.02","item_title":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on stockholder approval of an amendment to the 2021 Stock Incentive Plan increasing the share reserve by 2,000,000 shares. This is a compensatory arrangement affecting equity grants available to officers and directors, fitting the exec_compensation category. The materiality is high given the substantial increase in equity capacity and shareholder vote approval on July 7, 2026.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-11T00:15:58.677203+00:00","company_name":"Cellectar Biosciences, Inc.","ticker":"CLRB","filing_date":"2026-07-10"},{"id":15871,"accession_number":"0001104659-26-082719","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This Item 5.07 discloses the results of Cellectar Biosciences' Annual Meeting held on July 7, 2026, including voting outcomes on six proposals: election of Class III directors (Andrew Gu and Douglas J. Swirsky), approval of a 2,000,000-share increase to the 2021 Stock Incentive Plan, ratification of Deloitte \u0026 Touche LLP as independent auditor, advisory approval of named executive officer compensation, approval of warrant exercise for up to 39,618,078 shares, and adjournment (rendered moot). The detailed vote tallies for each proposal are material to investors assessing governance and capital structure decisions.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-11T00:15:58.677203+00:00","company_name":"Cellectar Biosciences, Inc.","ticker":"CLRB","filing_date":"2026-07-10"}]}